Please assess the completion status of the following clinical trial:

Trial Title: An Investigational Study to Evaluate BMS-986165 in Participants With Systemic Lupus Erythematosus

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Systemic lupus erythematosus (SLE) disease diagnosed ≥ 24 weeks before the screening visit~* Meets the Systemic Lupus International Collaborating Clinics (SLICC) classification criteria for SLE~* One of the following: elevated antinuclear antibodies (ANA) ≥ 1:80 or positive anti- double-stranded deoxyribonucleic acid (dsDNA) (positive includes indeterminate results) or positive anti-Smith (anti-Sm) as determined by the central laboratory~* Total Systemic Lupus Erythematosus Disease Activity Index 2000 (SLEDAI-2K) score ≥ 6 points and clinical SLEDAI-2K score ≥ 4 points with joint involvement and/or rash \[score must be confirmed by Central Review Services (CRS)\]~* Men and women must agree to follow specific methods of contraception, if applicable~Exclusion Criteria:~* Drug-induced SLE, certain other autoimmune diseases, and active, severe lupus nephritis~* SLE overlap syndromes such as scleroderma and mixed connective tissue disease~* Clinically significant abnormalities on chest x-ray or electrocardiogram (ECG)~* History of any significant drug allergy~Other protocol defined inclusion/exclusion criteria apply

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- BMS-986165 Dose 1 oral administration (Type: EXPERIMENTAL): None
- BMS-986165 Dose 2 oral administration (Type: EXPERIMENTAL): None
- BMS-986165 Dose 3 oral administration (Type: EXPERIMENTAL): None
- Placebo oral administration (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).